Janux starts dosing first patient in JANX014 phase 1 trial

April 16, 2026 4:01 PM

Janux Therapeutics (NASDAQ: JANX) announced it has dosed the first patient in a Phase 1 clinical trial of JANX014, a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found